In today’s ACT Brief, we examine why the future of AI in trials is a trusted orchestration system rather than a single model, how coordinators rate eSource-enabled workflows, and what a bipartisan bill proposes for reusable trial networks.
News|Articles|October 2, 2023
Emmes Appoints Peter Ronco as Chief Executive Officer
Advertisement
Emmes has announced that Peter Ronco has been named CEO, effective immediately.
Ronco succeeds Christine Dingivan, who will serve as a senior advisor to Executive Chairman Sastry Chilukuri and Emmes’ board of directors.
“Emmes has a 45-year legacy of scientific innovation and advancing public health. Peter’s leadership and operational expertise in the life sciences sector will be invaluable in our next phase of growth. I am excited to welcome Peter to the Emmes team,” said Kyle Peterson, managing director at New Mountain Capital and member of the board of the directors of Emmes, in a press release. “We are grateful for Christine’s leadership through an important chapter of growth and diversification after taking over from the original founders. She is a remarkable physician-entrepreneur and industry leader and will continue to support Peter, Sastry, and the board going forward.”
“Peter is a seasoned and innovative life sciences leader. He brings deep experience in running global operations with frontline use of technology and data science, which will propel our company forward,” added Chilukuri in a press release.
Ronco is a global pharmaceutical executive with experience in a number of R&D leadership positions over more than two decades. He most recently served as senior vice president, global development at Johnson & Johnson, responsible for the design and delivery of a drug development portfolio of more than 500 active clinical studies across all therapeutic areas and phases of development. He has also held senior roles with Bristol Myers Squibb, Accenture, and Pfizer.
“I am thrilled to be joining a company with an outstanding scientific track record and extensive credibility in clinical research,” said Ronco in a press release. “Emmes has a storied history, addressing some of the most complex health issues of our time. We look forward to an exciting future together as we partner with patients, clinical sites, government agencies, and biopharmaceutical companies to advance the next phases of scientific innovation and change the trajectory of health care.
“I believe that advances in decentralized clinical trials, data science, and generative AI offer huge potential to make clinical research even faster and more patient-focused. Embracing and accelerating the uptake of these approaches will allow us to have a greater impact on global health and biopharma innovation in the discovery and development of new medicines.”
Ronco is a graduate of Nottingham University in the UK and will be based out of Emmes’ Rockville, Maryland, headquarters.
Reference
Emmes Appoints Peter Ronco as Chief Executive Officer. (2023, October 2). Emmes.
Advertisement
Related to this article
The Faster Clinical Trials Act would create an FDA Center for Clinical Trial Innovation and aims to cut trial costs and enrollment time by at least 30%.
Standardized measurement across five oncology centers found that clinical research coordinators rated eSource-enabled workflows positively (Overall Mean Satisfaction 5.79 of 7), with reduced manual entry and electronic data transfer earning strong marks, while perceived reduction in sponsor and monitor queries lagged as the one domain below threshold.
In this video interview, Rajneesh Patil, global head of AI, digital, and innovation in clinical development at Syneos Health, describes the industry’s trajectory toward a unified intelligence orchestration environment—and explains why the future isn’t one model that knows everything, but a trusted system that brings the right evidence to the right human decision.
In today’s ACT Brief, we examine how sites can avoid both fear-driven and overly aggressive AI adoption, why community-based research needs sustained financial investment, and why patient access matters more than organizational size.
Pacing obesity trial enrollment, anchoring eligibility to stable real-world therapies, and building site and physician relationships improve retention and data quality more than aggressive recruitment or restrictive exclusion criteria do.
In this video interview, Rajneesh Patil, global head of AI, digital, and innovation in clinical development at Syneos Health, argues that CROs must act as orchestrators rather than aggregators—and that the real test of any AI ecosystem is whether it reduces sponsor coordination burden or just hands it back to them.
Syneos Health and Optum outline a joint model for trial planning, recruitment and site access, with no financial terms or timelines disclosed.
Advertisement
Advertisement
Trending on Applied Clinical Trials Online
1
Building Standardized Evidence for eSource-Enabled Clinical Trials: Multi-Site Validation of a Clinical Research Coordinator Satisfaction Methodology
2
Where the Industry Is Headed as Clinical, Operational, and Real-World Data Connect
3
Where AI Governance in Clinical Development Falls Short
4
Bipartisan Bill Would Build Reusable Clinical Trial Networks, With a Focus on Rare Disease
5